Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

TB Notes Newsletter

(PDF - 1 MB)

No. 2, 2014

Updated Cost-Effectiveness Analysis for 12-Dose Regimen

Dylan Shepardson, former Prevention Effectiveness Fellow in DTBE, published a letter in the International Journal of Tuberculosis and Lung Diseases (IJTLD) that updates the cost-effectiveness analysis for the 12-dose regimen for LTBI treatment. This analysis is based upon the lower price for rifapentine offered by Sanofi. The letter includes reference to a website where TB program staff can input local costs for various elements to best inform local policy for the use of the 12-dose regimen.

Though Dylan has returned to Mount Holyoke, we are fortunate that he continues to engage in DTBE modeling projects.

Reported by William Mac Kenzie, MD
Div of TB Elimination


Shepardson D, Mac Kenzie WR. Update on cost-effectiveness of a 12-dose regimen for latent tuberculous infection at new rifapentine prices. Int J Tuberc Lung Dis 2014; 18(6): 751–753.

Top of Page